Suppr超能文献

日本变态反应学会屋尘螨变应原疫苗标准化特别工作组报告 - 二次发表

Japanese Society of Allergology task force report on standardization of house dust mite allergen vaccines - secondary publication.

作者信息

Takai Toshiro, Okamoto Yoshitaka, Okubo Kimihiro, Nagata Makoto, Sakaguchi Masahiro, Fukutomi Yuma, Saito Akemi, Yasueda Hiroshi, Masuyama Keisuke

机构信息

Task Force for House Dust Mite Allergen Standardization of the Committee for Allergens and Immunotherapy of the Japanese Society of Allergology, Tokyo, Japan; Atopy (Allergy) Research Center, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Task Force for House Dust Mite Allergen Standardization of the Committee for Allergens and Immunotherapy of the Japanese Society of Allergology, Tokyo, Japan; Department of Otorhinolaryngology-Head and Neck Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.

出版信息

Allergol Int. 2015 Apr;64(2):181-6. doi: 10.1016/j.alit.2015.01.005. Epub 2015 Mar 4.

Abstract

BACKGROUND

In the 1990s, the Japanese Society of Allergology (JSA) standardized Japanese cedar pollen allergen vaccines. In the present study, the task force for house dust mite (HDM) allergen standardization of the Committee for Allergens and Immunotherapy of JSA reports the standardization of HDM allergen vaccines in Japan.

METHODS

In vivo allergenic potency was determined by intradermal testing of 51 Japanese adults with positive serum specific IgE to HDM allergens. In vitro total IgE binding potency was analyzed by competition ELISA using a pooled serum, with sera obtained from 10 allergic patients. The amounts of HDM group 1 (Der 1) and group 2 major allergens in eight HDM allergen extracts were measured by sandwich ELISAs. Correlation between the in vitro total IgE binding potency and major allergen levels was analyzed.

RESULTS

We selected a JSA reference HDM extract and determined its in vivo allergenic potency. The in vitro total IgE binding potency significantly correlated with Der 1 content, group 2 allergen content, and their combined amount, indicating that measurement of major allergen contents can be used as a surrogate in vitro assay.

CONCLUSIONS

The task force determined the in vivo allergenic potency (100,000 JAU/ml) and Der 1 content (38.5 μg/ml) of the JSA reference HDM extract, selected the measurement of Der 1 content as the surrogate in vitro assay, and decided that manufacturers can label a HDM allergen extract as having a titer of 100,000 JAU/ml if it contains 22.2-66.7 μg/ml of Der 1.

摘要

背景

20世纪90年代,日本变态反应学会(JSA)对日本雪松花粉变应原疫苗进行了标准化。在本研究中,JSA变应原与免疫治疗委员会屋尘螨(HDM)变应原标准化特别工作组报告了日本HDM变应原疫苗的标准化情况。

方法

通过对51名血清特异性IgE对HDM变应原呈阳性的日本成年人进行皮内试验来测定体内变应原效力。使用来自10名过敏患者的混合血清,通过竞争ELISA分析体外总IgE结合效力。通过夹心ELISA测定8种HDM变应原提取物中HDM第1组(Der 1)和第2组主要变应原的含量。分析体外总IgE结合效力与主要变应原水平之间的相关性。

结果

我们选择了一种JSA参考HDM提取物并测定了其体内变应原效力。体外总IgE结合效力与Der 1含量、第2组变应原含量及其总量显著相关,表明主要变应原含量的测定可作为替代体外试验。

结论

特别工作组确定了JSA参考HDM提取物的体内变应原效力(100,000 JAU/ml)和Der 1含量(38.5 μg/ml),选择Der 1含量的测定作为替代体外试验,并决定如果制造商生产的HDM变应原提取物含有22.2 - 66.7 μg/ml的Der 1,则可标记其效价为100,000 JAU/ml。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验